New Approaches in Cancer Treatment

Rutuja Kardile¹, Komal Andhale², Sneha Panchal³,
Dr. Urmilesh Jha⁴, Mr. Sachin Vijapure⁵, Mr. Rushikesh Sutar⁶

Pursuing B pharm in sarsam college of pharmacy, Pune, Maharashtra, India.
Honorable Principle, Sarsam college of pharmacy, Pune.
Professor @ Sarsam college of Pharmacy, Pune.
Lecturer @ sarsam college of pharmacy, Pune.

ABSTRACT: Cancer is a global health problem responsible for one in six deaths worldwide. Treating cancer has been a highly complex process. Conventional treatment approaches, such as surgery, chemotherapy, and radiotherapy, have been in use, while significant advances are being made in recent times, including stem cell therapy, targeted therapy, ablation therapy, nanoparticles, natural antioxidants, radionics, chemodynamical therapy, sonodynamic therapy, and ferroptosis-based therapy. Current methods in oncology focus on the development of safe and efficient cancer nanomedicines. Stem cell therapy has brought promising efficacy in regenerating and repairing damaged tissues by targeting both primary and metastatic cancer foci, and nanoparticles brought new diagnostic and therapeutic options. Targeted therapy possessed breakthrough potential inhibiting the growth and spread of specific cancer cells, causing less damage to healthy cells. Ablation therapy has emerged as a minimally invasive procedure that burns or freezes cancers without the need for open surgery. Natural antioxidants demonstrated potential tracking down free radicals and neutralizing their harmful effects thereby treating or preventing cancer. Several new technologies are currently under research in clinical trials, and some of them have already been approved. This review presented an update on recent advances and breakthroughs in cancer therapies.

Keywords: Cancer, treatment, stem cell, targeted drugs, ablation, natural antioxidants, gene therapy.

1. INTRODUCTION
Cancer is a global health problem responsible for one in six deaths worldwide. In 2020, there were an estimated 19.3 million new cancer cases and about 10 million cancer deaths globally. Cancer is a very complicated sequence of disease conditions progressing gradually with a generalized loss of growth control. There were only a few options of cancer treatment for patients for many decades which include surgery, radiation therapy, and chemotherapy as single treatments or in combination. But recently, many pathways involved in cancer therapy progression and how they can be targeted has improved dramatically, with combinatorial strategies, involving multiple targeted therapies or “traditional” chemotherapeutics, such as the tisanes and platinum compounds, being found to have a synergistic effect. New approaches, such as drugs, biological molecules, and immune-mediated therapies, are being used for treatment even if the excepted therapy level has not reached that resists the mortality rate and decreases the prolonged survival time for metastatic cancer.

The creation of a new revolution in neoplastic cancer or targeting drugs depends on the pathways and characteristics of different tumour entities. Chemotherapy is considered the most effective and widely used modality in treating cancers as used alone or in combination with radiotherapy. Genotoxicity is how chemotherapy drugs target the tumour cells mainly producing reactive oxygen species that largely destroy tumour cells. Hormonal treatments are also widely used for cancer malignancies and considered as cytostatic because it restricts tumour development by limiting the hormonal growth factors acting through the direction of hypothalamic–pituitary–gonadal axis (HPGA), hormone receptor blockage, and limiting of adrenal steroid synthesis.

In this review, a general overview of the most advanced and novel cancer therapies was provided. In addition, also new strategies currently under investigation at the research stage that should overwhelm the drawbacks of standard therapies; different strategies to cancer diagnosis and therapy; and their current status in the clinical context, underlining their impact as innovative anti-cancer approaches.

2. HISTORY OF CANCER
The history of medicine is both a study of medicine throughout history as well as a multidisciplinary field of study that seeks to explore and understand medical practices, both past and present, throughout human societies. The history of cancer is a story of theories about the causes and effects of the disease as well as of the continuing specific discoveries regarding the disease's structure, treatments, and methods for diagnosis. Furthermore, this history is also embedded in the more general advances within medicine, such as new methods concerning surgery and discoveries regarding new techniques and instruments. In such a broad sense, the history of cancer may be subdivided into distinct periods, where the first covers the relatively long ancient and medieval periods based on what we by now consider as incorrect theories about the nature of cancer. A transitional period of theories trying to replace the ancient theories followed but was quickly replaced by a period based on the cellular theory, proposing that both normal and cancerous cells come from cells of common origin. There were a series of new techniques for diagnosis and treatments from the mid-19th century and onward. More recently, further advances within this prolonged cellular period have been made based on new insights into genetics and other scientific fields.
3. **CAUSES OF CANCER**
Cancer is caused by changes (mutations) to the DNA within cells. The DNA inside a cell is packaged into many individual genes, each of which contains a set of instructions telling the cell what functions to perform, as well as how to grow and divide. Errors in the instructions can cause the cell to stop its normal function and may allow a cell to become cancerous. Some of these causes are:
   - A) Cancer syndromes.
   - B) Physical and chemical agents.
   - C) Smoking. D) Alcohol.
2. Infection and inflammation.
4. Radiation.
6. Rare causes.
   - A) Organ transplantation.

4. **TYPES OF CANCER**
There are more than 100 types of cancer. Types of cancer are usually named for the organs or tissues where the cancers form. For example, lung cancer starts in the lung, and brain cancer starts in the brain. Cancers also may be described by the type of cell that formed them, such as an epithelial cell or a squamous cell. The information on specific types of cancer based on the cancer’s location in the body or by using our A-to-Z List of Cancers. We also have information on childhood cancers and cancers in adolescents and young adults. Here are some categories of cancers that begin in specific types of cells:
- **CARCINOMA**
- **SARCOMA**
- **LEUKAEMIA**
- **LYMPHOMA**
- **MULTIPLE MYELOMA**
- **MELANOMA**

5. **CANCER TREATMENT MODE**
We can see cancer treatment modalities by dividing them into conventional (traditional) and advanced or novel or modern categories. In this era worldwide, over half of all ongoing medical treatment trials are focusing on cancer treatments. Entities, such as the type of cancer, its site, and severity, guide to select treatment options and its progress. The most widely used traditional treatment methods are surgery, chemotherapy, and radiotherapy, while modern modalities include hormone therapy, anti-angiogenic, stem cell therapies, immunotherapy, and dendritic cell-based immunotherapy.
- **CONVENTIONAL CANCER THERAPIES**
The most recommended conventional cancer treatment strategies include surgical resection of the tumour’s followed by radiotherapy with x-rays and/or chemotherapy. Of these modalities, surgery is most effective at an early stage of disease progression. Radiation therapy can damage healthy cells, organs, and tissues. Although chemotherapy has reduced morbidity and mortality, virtually all chemotherapeutic agents damage healthy cells, especially rapidly dividing and growing cells. Drug resistance, a major problem with chemotherapy, is a phenomenon wherein cancer cells that initially were suppressed by an anti-cancer drug develop resistance to the drug. This is caused primarily by reduced drug uptake and increased drug efflux. Limitations of conventional chemotherapeutic modality, such as dosage selection difficulty, lack of specificity, rapid drug metabolism, and mainly harmful side effects.
- **ADVANCED AND INNOVATIVE CANCER THERAPIES**
Among the obstacles of cancer, drug resistance and its delivery systems are mostly problematic in cancer cure and decreasing signs and symptoms; but currently, there are many approved treatment approaches and drugs. The efficiency of conventional cancer is reduced due to tumour pathology and architectural abnormality of tumour tissue blood vessels. The following are the advanced and innovative cancer therapy types with their benefits and challenges.

A) **STEM CELL THERAPY**
Stem cells are undifferentiated cells present in the bone marrow (BM) with an ability to differentiate into any type of body cell. Stem cell therapeutic strategy is also one of the treatment options for cancer which are considered to be safe and effective. Application of stem cell is yet in the experimental clinical trial; for example, their use in the regeneration of other damaged tissue is being explored. Mesenchymal stem cells (MSCs) are currently being used in trials that are delivered from the BM, fat tissues, and connective tissues.

I. **PLURIPOTENT STEM CELLS**
Embryonic stem cells (ESCs) isolated from the uniform inner mass cells of the embryo possess the flexibility to administer rise to any or all kinds of cells except those within the placenta. In 2006, the invention of Yamanaka factors to induce pluripotent stem cells (iPSCs) from physical cells in a culture marked a breakthrough in cell biology. Avoiding ethical issues from embryo destruction, iPSCs and ESCs have the same characteristics. Hematopoietic embryonic stem cells (hESCs) and iPSCs are currently used for the induction of effector T cells and natural killer (NK) cells, and anti-tumor vaccine preparation.

II. **ADULT STEM CELLS**
Adult stem cells (ASCs) groups often used in tumor therapy include hematopoietic stem cells (HSCs), MSCs, and neural stem cells (NSCs). HSCs, located in BM, can form all mature blood cells in the body. Currently, only approved by the Food and Drug Administration (FDA) is the infusion of HSCs derived from cord blood to treat multiple myeloma and leukemia.
MSCs are found in many tissues and organs, playing important roles in tissue repair and regeneration into cells, such as osteocytes, adipocytes, and chondrocytes. MSCs have special biological characteristics and are used as complimentary with other approaches in treating tumours. NSCs can self-renew and generate new neurons and glial cells and are used for treating both primary and metastatic breast and other tumours.

III. CANCER STEM CELLS
Cancer stem cells (CSCs) are generated in normal stem cells or precursor/progenitor cells by the epigenetic mutations process. Their role in tumor treatment includes cancer growth, metastasis, and recurrence, so that it could give promise in the treatment of solid tumours. Stem cells have several action mechanisms in treating the tumor. The homing process is one mechanism which is a rapid migration of HSCs into defined stem cell niches in BM after that the transplants undergo the engraftment process before giving rise to specialized blood cells. This mechanism is dependent on the active interaction between stem cell CXCR4 receptors and requires their interaction with endothelial cells through LFA-1, VLA-4/5, CD44, and the secretion of matrix degradable enzyme MMP-2/9. The second mechanism is the tumor-tropic effect in which the migration of MSCs toward tumor microenvironment (TM) after attraction by CXCL16, SDF-1, CCL-25, and IL-6 secreted by tumor cells and differentiation of MSCs within the tumor cells which contributes to tumor stromal development. Stem cells also act by paracrine factor secretion, including extracellular vehicles (EVs) and soluble materials, and their differentiation capacity, such as transplanted HSCs, can give rise to all blood cell types.

Generally, cancer treatment using stem cell therapy by various strategies, including transplantation of HSC, MSC infusion, therapeutic carriers, generation of immune effector cells, and vaccine production. The stem cell cancer therapy approach confronted the following side effects: (1) tumorigenesis, (2) adverse events in allogeneic HSC transplantation, (3) drug toxicity and drug resistance, (4) increased immune responses and autoimmunity, and (5) viral infection. Despite several successes, there are challenges, such as therapeutic dose control, low cell targeting, and retention in tumor sites, that should be investigated and overcome in the future. In addition, existing results from stem cell technologies are highly encouraging for tumor treatment but it still needs further efforts to improve the safety and efficacy before they could enter clinical trials.

B) TARGETED DRUG THERAPY
Targeted cancer therapies are drugs or other substances which are sometimes interchangeably used as “molecularly targeted drugs,” “molecularly targeted therapies,” and “precision medicines.” Those drugs’ mechanism of action is by interfering with growth molecules which leads to blocking the growth and spreading of cancer. Tumor initiation and progression are determined by the TM of an atypical tumor which comprises endothelial cells, pericytes, smooth muscle cells, fibroblasts, various inflammatory cells, dendritic cells, and CSCs. There are various signalling mechanisms and pathways that TM-forming cells dynamically interact with the cancerous cells which are suitable for sustaining a reasonably high cellular proliferation. So, it is the area of research interest using TM conditions to mediate effective targeting measures for cancer therapy.

Selectively treating cancer cells with conventional chemotherapy is difficult since it is similar to normal cells. So those problems are intervened by cellular mechanisms, such as cell cycle arrest, apoptosis induction, proliferation prevention, and interfering with metabolic reprogramming by targeted drug therapy agents. Modifying TM and targeting TM for drug delivery for effective treatment are two strategies that can be used for the treatment of cancer. Targeted therapy drugs do work in different ways from standard chemotherapy drugs treatment like attacking cancer cells while doing less damage to normal cells which is a programming that sets them apart from normal, healthy cells.

Using targeted therapy markedly increased the survival rate for some diseases, for example, from 17% to 24% in patients with advanced pancreatic cancer, the addition of erlotinib to standard chemotherapy. Imatinib has had a dramatic effect on chronic myeloid leukaemia, and rituximab, sunitinib, and trastuzumab have revolutionized the treatment of renal cell carcinoma and breast cancer, respectively.

We can classify the targeted cell agents based on the mechanism of their work or their target site. Some enzymes serve as signals for cancer cells to grow. Some targeted therapies inhibit enzymes that are signals for cancer cells to grow. These drugs are called enzyme inhibitors. Blocking these cell signals can inhibit cancer from getting bigger and spreading.

Some targeted therapies are called apoptosis-inducing drugs because they are aimed right at the parts of the cell that control whether cells live or die. The examples are serine/threonine kinase, protein kinase B (PKB/Akt), which promotes cell survival, and inhibitors of this protein are in the preclinical phase.

These agents stop the tumours from making new blood vessels which helps cut off the tumours’ blood supply so that tumours cannot grow. In addition, they arrest tumor growth that involves by curtailing blood supply to the tumor by inhibiting angiogenic factors, such as vascular endothelial growth factor (VEGF) or its receptors. The study showed the survival of patients with advanced colorectal carcinoma extended by months after the use of Avastin (bevacizumab) in combination with 5-fluorouracil-based chemotherapy.

- TYPES OF TARGETS AGENT
  I. MONOCLONAL ANTIBODIES
Antibody drugs are man-made versions of immune system proteins administered intravenously to attack certain targets on cancer cells. They contain a more proportion of human components than murine components. Their attack mechanisms of action are recruiting host immune functions to attack the target cell, binding to ligands or receptors thereby interrupting essential cancer cell processes, and carrying a lethal payload, such as radioisotope or toxin, to the target cell. Gemtuzumab is an example of a CD-33-specific monoclonal antibody currently used for AML treatment by conjugating with calicheamicin. In addition, ibritumomab tiuxetan is an anti-CD20, a 90Y metal isotope-based is developed in clinical therapy. Delivery of active therapeutics, prodrug activation enzymes, and chemotherapy toxins are also another use of target agents of monoclonal antibodies.
II. SMALL MOLECULE INHIBITORS
These are smaller proteins in size (⩽500 Da) than monoclonal antibodies, so that they can simply translocate through plasma membranes and can be taken orally. Their main function is interrupting cellular processes by interfering with the intracellular signalling of tyrosine kinases which leads to the inhibition of tyrosine kinase signalling and initiates a molecular cascade that can lead to the inhibition of cell growth, proliferation, migration, and angiogenesis in malignant tissues. Examples of small molecule inhibitors are gefitinib and erlotinib which inhibit epidermal growth factor receptor (EGFR) kinase and EGFR in non-small cell lung cancer (NSCLC) patients, respectively. There are also lapatinib and sorafenib which act on the inhibition of EGFR/Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) for ERBB2-positive breast cancer and VEGFR kinase, in renal cancer.

C) ABLATION CANCER THERAPY
Ablation is a treatment technique that destroys tumors without removing them mostly indicated for small-size tumors of less than 3 cm and the surgical option is contraindicated. Ablation is also used with embolization for larger tumors. However, this technique might not be indicated for treating tumors near major blood vessels, the diaphragm, or major bile ducts due to destroying some of the normal tissue around the tumor.

I. THERMAL ABLATION
This technique uses extreme hyperthermia or hypothermia to destruct tumor tissue concentrating on a focal zone in and around the tumor. Similar to surgery, thermal ablation removes the tumor and a 5–10 mm thick margin of seemingly normal tissue but the tissue is killed in situ and then absorbed by the body later. The procedure is similar to surgery using an open, laparoscopic, or endoscopic approach but is commonly applied using a percutaneous or non-invasive approach. The type of tumor, site, physician’s choice, and health status determine the approach. Radiofrequency ablation (RFA), microwave ablation, high-intensity focused ultrasound, and cryoablation are currently being used in the clinical setting. Cryoablation uses a hyperthermic modality to induce tissue damage by a freeze-thaw process against others. All these treatments operate on the principle of hyperthermia except cryoablation. Of all the ablation techniques, cryoablation demonstrated the highest potential to elicit a post-ablative immunogenic response. Recent studies showed additional to tissue disruption RFA and cryoablation can modulate the immune system that they were applied as therapy on TM and in the systemic circulation. Evidence has shown that ablation procedures affect carcinogenesis due to its local inflammatory response leading to an immunogenic gene signature. The advantage of this procedure over surgery is that it provides a minimal (e.g., percutaneously or laparoscopically) or non-invasive approach to cancer therapy and gets attention as an alternative to standard surgical therapies.

Radiofrequency ablation
- Repeatability
- Widely available and proven

Microwave ablation
- Uniform ablation zone
- Larger ablated area
- No heat-sink effect
- Less ablation time

Lung malignancies
- Single therapy
- Combined therapy

Cryoablation
- Suitable for lesions near large vessels or peripherally
- Less painful

Fig 1. Ablation for lung

II. CRYOABLATION
Cryoablation is one of the ablation techniques which ablates the extensive tissue by freezing to lethal temperatures followed by liquid formation, causing extensive tissue. Benign and malignant primary tumors are mostly treated by this therapy. James Arnott reported that the freezing temperatures can impair cancer cell viability after he attempted the usage of cold temperatures by salt and ice solutions for the generation of local numbness before surgical operations in the nineteenth century. He suggested cryoablation as an attractive therapeutic option and increased a patient’s survival.
Cryoablation techniques are based on the principle of the Joule–Thomson effect which was studied in the 1930s by many researchers and concluded using liquid CO2 under high pressure, liquid air, and liquid oxygen to achieve the cooling effect and the subsequent formation of ice crystals so employed to treat lesions, warts, and keratosis. However, after 1950, Allington replaced liquid N2 for the treatment of various skin lesion disorders.

III. RFA THERAPY

RFA is a minimally invasive procedure and an image-guided technique using hyperthermic (high-frequency electrical currents) conditions to destroy cancer cells. Imaging techniques, such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), guide needle electrodes into a tumor cell. Generally, RFA is the most effective approach for treating small-size tumours of less than 3 cm in diameter. RFA can be used in combination with other conventional cancer treatment options. After starting the use of deployable devices or multiple-electrode systems, RFA can treat medium tumours (up to 5 cm diameter).

D) GENE THERAPY

Gene therapy is the insertion of a normal copy of a defective gene in the genome to cure a specific disorder. The first application dates back to 1990 when a retroviral vector was exploited to deliver the adenosine deaminase (ADA) gene to T cells in patients with severe combined immunodeficiency (SCID). Approximately, about 2900 gene therapy clinical trials are currently ongoing, two-third of which are related to cancer. Strategies, such as expression of proapoptotic and chemo sensitizing genes, expression of wild-type tumor suppressor genes, expression of genes able to solicit specific anti-tumor immune responses, and targeted silencing of oncogenes, are under evaluation for cancer gene therapy. Thymidine kinase (TK) gene delivery is effective for the administration of prodrug ganciclovir to activate its expression and induce specific cytotoxicity. The p53 tumor suppressor gene which is vectors carrying has been assessed for the clinical purpose very recently. ONYX-015 has been tested in NSCLC patients and gave a high response rate when given alone or combined with chemotherapy. Medicine, a recombinant adenovirus carrying wild-type p53-induced complete disease regression in head and neck squamous cell cancer had similar success when combined with radiotherapy. Some challenges that have been faced with gene therapy are the selection of the right conditions and the choice of the best delivery mechanism. Identified drawbacks of this therapy are genome integration, limited efficacy in specific subsets of patients, and high chances of being neutralized by the immune system. Basic research and medical translation used RNA interference (RNAi) as an efficient technology that able to produce targeted gene silencing. RNA-induced silencing complex (RISC) mediates the targeted gene silencing process by cleaving the messenger RNA (mRNA) and interference with protein synthesis. A siRNAs can be designed to block desired targets, involving cell proliferation and metastatic invasion; hence, precise molecular mechanisms are a triggering factor for tumor formation. This method relies on siRNA-mediated gene silencing of anti-apoptotic proteins, transcription factors (i.e., c-my gene) or cancer mutated genes (i.e., K-RAS).

Advantages of siRNA-based drugs are safety, high efficacy, specificity, few side effects, and low costs of production. However, occasionally, they can induce off-target effects or elicit innate immune responses, followed by specific inflammation. Delivery methods currently under study are chemical modification (insertion of a phosphonothioate at 3' end, introduction of a 2' O-methyl group, and modification by 2,4-dinitrophenol) and lipid encapsulation, or conjugation with organic molecules (polymers, peptides, lipids, antibodies, small molecules) efficiently target to spontaneously cross cell membranes of naked siRNAs. Interaction of cationic liposomes with negatively charged nucleic acids facilitates easy transfection by simple electrostatic interactions. They can be constituted by 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and N-[1-(2,3-dioleoyloxy) propyl]-N, Trimethylammonium methyl sulphate (DOTMA). Currently, a Phase I clinical trial is recruiting patients for evaluating the safety of Eph receptor A2 (EphA2) targeting 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) encapsulated siRNA (siRNA-EphA2- DOPC) in patients with advanced and recurrent cancer. siRNAs can be concentrated in cationic polymers, such as chitosan, cyclodextrin, and polyethyleneimine (PEI). CALAA-01 is one of the cyclodextrin polymers conjugated with human transferrin is being entered a Phase I clinical trial. CALAA has been used as an anti-cancer by forming small cationic nanoparticles and loading with human epidermal growth factor receptor 2 (HER-2 receptor)-specific synapse II clinical trial has been started to evaluate Local Drug Elute (siG12D LODER) directed to mutated Kirsten rat sarcoma (K-RAS) oncogene for the treatment of advanced pancreatic cancer. Conjugating to peptides, antibodies, and aptamers improves stability during circulation and enhances cellular uptake of siRNAs. The introduction of nanocarriers has largely improved siRNAs stability, pharmacokinetics and biodistribution properties, and targeting specificity. Polyallylamine phosphate nanocarriers have been developed to release siRNAs in the cytoplasm after disassembly at low endosomal pH.

Dose correction and variabilities between individuals and different stages of disease are challenging issues on clinical translation of the siRNA-based approach. In the future, the needed research is on setting up the best-personalized therapy and toward controlled release to reach only specific targets on treating the tumor.

E) NATURAL ANTIOXIDANTS

Day to day, the anatomy undergoes many exogenous insults, such as ultraviolet (UV) rays, pollution, and tobacco smoke, that end in the assembly of reactive species, particularly oxidants and free radicals, liable for the onset of many diseases, together with cancer. These molecules can even be made as a consequence of clinical administration of medication; however, they are additionally naturally created within our cells and tissues by mitochondria and peroxisomes, and from macrophages metabolism, throughout traditional physiological aerobic processes. Oxidative stress and radical oxygen species can significantly change the regulation of transcription factors by damaging the DNA and other bio-macromolecule. Vitamins, polyphenols, and plant-derived bioactive compounds are natural antioxidants used as preventive and therapeutic drugs against these molecules that damage the body due to their anti-inflammatory and antioxidant properties. Studies added to cancer therapy after appreciating their anti-proliferative and proapoptotic properties. Compounds, such as vitamins, alkaloids,
flavonoids, carotenoids, curcumin, berberine, quercetin, and others, are examples of natural antioxidants screened in vitro and in vivo.

6. CURRENT CLINICAL TRIALS
In recent years, analysis of cancer medication has taken outstanding steps toward more practical, precise, and fewer invasive cancer treatments in the research of clinical trials.

Currently, the most frequent entries focusing on cancer therapies in the database of clinical trials include the terminologies stem cell, targeted therapy, immune-therapy, and gene therapy because they are very promising and effective.

7. GOALS OF CANCER THERAPY
Treatment planning includes discussion with patients about their goals of therapy and whether those goals are realistic.

1. Prevention
   a) Primary cancer prevention: Measures taken to avoid carcinogen exposure and promote health. Steps taken to prevent disease development (e.g., avoidance of tobacco products, immunization against HPV).
   (1) Chemoprevention: The use of selected pharmacologic agents to prevent cancer in high-risk individuals, such as the administration of tamoxifen to women whose personal health history indicates they are at a statistically increased risk for developing breast cancer.
   (2) There has been discussion related to the role of nutritional epidemiology in the identification of nutritional or chemopreventive approaches to colon cancer, but that has yet to be confirmed.
   c) Tertiary cancer prevention: Monitoring for and/or preventing recurrence of the original cancer or secondary malignancies.

2. Cure: Defined as the prolonged absence of detectable disease. This is the desired outcome for all patients but is not always achievable.

3. Control: When cure is not possible, the goal is to allow patients to live longer than if therapy had not been given. Treatment often extends life and may prevent the growth of cancer cells without complete elimination of disease or may reduce existing disease.

4. Palliation: Palliative cancer care is the integration of therapies that address the multiple issues that cause suffering in patients with cancer and their families. In 2009, the American Society of Clinical Oncology (ASCO) Board of Directors...
advocated that palliative care be offered to all patients from the time of diagnosis to death. Palliation involves reduction of side effects and symptoms, including pain. It may include surgery, radiation therapy, chemotherapy, or biotherapy, individually or in combination.

8. Cancer Care: - Health plan
Best Cancer Insurance Plan in India 2022
Cancer Insurance is a special kind of insurance that is designed to protect the policyholder from bearing the high costs associated with cancer. Cancer insurance helps secure your financial situation and bears the costs related to getting quality treatment for cancer, offering financial protection. A cancer insurance policy offers coverage against all cancer stages along with the dual benefit of a lump-sum payment in addition to income on the diagnosis of a major stage. A cancer insurance policy offers various benefits such as covering expenses associated with hospitalization, chemotherapy, radiation, surgery, etc.

Cancer is not just a disease, it is a different story of pain, distress, emotional breakdown, survival risk, and whatnot. Cancer not only affects the patient but the entire family and those connected closely. And unfortunately, this disease is on the spike all around the globe. Talking specifically about India, cancer cases are expected to increase by 12% by 2025 as suggested in a report by the Indian Council of Medical Research (ICMR) and the Bengaluru-based National Centre for Disease Informatics and Research. Cancer is not limited to a person, gender, geography, or demography, it can affect anyone anywhere anytime. The report also reveals that by 2025 the number of cancer cases in men may reach 7,63,575 and 8,06,218 in women. These figures are alarming and every living being is vulnerable to this deadly disease. Fighting against cancer requires a lot of strength, a positive attitude, zeal to survive, emotional support, and huge financial resources.

According to a national survey, the average total cancer care expenditure in 2017-2018 was around Rs. 1,16,218 (public hospitals). Whereas in private hospitals, the cost was approximately Rs. 1,41,774. However, public hospitals are comparatively more economical than private hospitals for cancer treatment but the overall cost is still expensive. Moreover, the medical inflation over these years has sky-rocketed the cancer care treatment cost.

In such a situation, the best companion to manage cancer care expenses is cancer insurance. A comprehensive cancer insurance plan can relieve you and your family from the financial burden while dealing with an already stressful medical condition.

9. Factors affecting treatment response
1. Pre-treatment comorbidities and performance status: Patients with comorbid conditions and those who have been heavily pre-treated may be less able to tolerate the side effects and toxicities of chemotherapy, thus affecting dose intensity and treatment planning.

After tumour type, performance status or activity level is the most important factor to consider when determining appropriate and tolerable treatment. Patients who have poorer performance scores (e.g., bed ridden) may be unable to withstand the rigors of an aggressive treatment regimen and may experience decreased QOL. Patients who are fully active or have mild symptoms respond more frequently to treatment and survive longer than those who are less active or experience more symptoms.

2. Tumour burden: The inverse relationship between the number of tumour cells and response implies that the smaller the tumour, the higher the rate of response (Torriti, 2011). As tumour mass increases, the growth rate slows, decreasing the effectiveness of antineoplastic there. Additionally, large solid tumours may have inadequate blood flow, which inhibits the ability of the chemotherapy to reach the entire tumour.

3. Rate of tumour growth: Tumour doubling time (time for the tumour to double in mass) and growth fraction (proportion of proliferating cells in relation to the total number of tumour cells) are important factors affecting response. Cytotoxic chemotherapy agents are most effective if given during the growth phase of the tumour, when a high percentage of cells are susceptible to the effects of that agent.

4. Hormone receptor status
a) Presence of estrogenic receptors (ERs) and/or progesterone receptors (PRs) is prognostic for breast cancer. Patients who are ER/PR positive demonstrate better overall survival rates Tumours that grow more rapidly in the presence of a specific hormone may be suppressed with an antihormonal agent.

b) Hormone receptor status has become increasingly important in cancer therapy.

5. Drug resistance: Many patients experience relapse because tumours become resistant to the drugs used to treat therapy.

a) Genetic instability of tumour cells and the emergence of drug resistance are currently considered the most significant determinants of tumour response to treatment.

b) Complex biochemical pathways involving a multitude of receptors and enzymes are implicated and depend up on the type of cell and chemotherapy agent.

c) Research points to a complex interaction among cytotoxic agents, chemical messengers (transporters that deliver drugs to the tumour), and the genetic ability of malignant cells to avoid chemotherapy-induced apoptosis because of their high rate of genetic instability.

d) Genomic changes, originally presenting in small subclones of cancer cells, often underlie acquired resistance, such as ABL mutation in chronic myeloid leukaemia and MET in non-small cell lung cancer. Genomic differences have an important role in determining how a given cancer will respond to treatment.

e) Tumour cells may be inherently resistant to antineoplastic agents or develop resistance after drug exposure because of the emergence of resistant clones.

CONCLUSION
Trends of cancer is the key step for the betterment of patients with major health issues related to cancer. It provides the technologies and innovation to detect the cancer in early stages. Cancer research crucial to improve the prevention, detection,
and treatment of these cancers, and ensure that survivors live longer, better quality lives. Trends of cancer is important to give various opportunity for patients to improve their health. Cancer policies for financial support. A plan for the diagnosis and treatment of cancer is a key component of any overall cancer control plan. Its main goal is to cure cancer patients or prolong their life considerably, ensuring a good quality of life. Current methods in oncology focus on the development of safe and efficient cancer nanomedicines. Targeted medical care helped rising the biodistribution of recent or already tested chemotherapeutical agents around the specific tissue to be treated; different methods, such as sequence medical care, siRNAs delivery, therapy, and inhibitor molecules, supply new potentialities to cancer patients. Gene therapy acts by direct in situ insertion of exogenous genes into benign tumours. Noticeably, stem cells can be used as regenerative medicine, therapeutic carriers, drug targeting, and generation of immune cells because of having unique biological actions on other cells. On the opposite hand, thermal ablation and magnetic hyperthermia are promising alternatives to the growth surgical process. Much progress has been made, but many others are likely to come soon, producing more and more personalized therapies. Further development and refinement of drug delivery systems are essential for improving therapeutic outcomes.

REFERENCE
2. chandrakant R.kokare.pharmaceutical Microbiology and Biotechnology,Nirali Publication,page no:43.9-48.11